Glycated hemoglobin News and Research

RSS

Participatory pay-for-performance improves primary care

Both quality of care measures and patient experience may be achieved through the introduction of a participatory pay-for-performance program, study findings indicate.

1 Oct 2012

Intarcia announces results from ITCA 650 phase 2 study on type 2 diabetes

Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes will be presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany on Wednesday, October 3, 2012.

29 Sep 2012

Extended release exenatide outperforms twice daily regimen

Once-weekly extended-release exenatide is a more effective treatment than twice-daily exenatide at improving glucose control among Japanese individuals with diabetes, report researchers.

24 Sep 2012

Biodel initiates BIOD-123 Phase 2 trial in Type 1 diabetes

Biodel Inc. today announced the initiation of a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting mealtime insulin candidate, BIOD-123.

13 Sep 2012

MADONNA: Personalized antiplatelet therapy savior for angioplasty patients?

Personalized antiplatelet treatment may improve cardiac outcomes after percutaneous coronary intervention, researchers suggest.

4 Sep 2012

Herpes virus eventually impairs glucose regulation

The common herpes virus cytomegalovirus may be a risk factor for the development of Type 2 diabetes among elderly individuals, show study findings.

3 Sep 2012

Low blood pressure increases diabetes mortality risk

Tight blood pressure control fails to confer a survival benefit in patients newly diagnosed with Type 2 diabetes, and may even increase mortality risk when low blood pressure levels are achieved, UK investigators have discovered.

3 Sep 2012

Diabetes prevention: an interview with Julian Baines, CEO of EKF Diagnostics

NICE public health guideline 38 ‘Preventing type 2 diabetes: Risk identification and interventions for individuals at high risk’.

From EKF Diagnostics 3 Sep 2012

Personalized antiplatelet treatment leads to better outcomes in patients undergoing PCI

Personalized antiplatelet treatment leads to better outcomes than standard antiplatelet treatment in patients undergoing coronary stent implantation, according to results from the MADONNA study presented at ESC Congress 2012.

28 Aug 2012

Insulin glargine retards progression of atherosclerosis in high-risk people

A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.

27 Aug 2012

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin.

18 Aug 2012

Biopsy required for accurate renal diagnosis in diabetes

People with diabetes and symptoms of nephropathy should undergo renal biopsy before a diagnosis of diabetic nephropathy is assumed, report researchers.

17 Aug 2012

NICE guidelines for diabetes prevention welcomed by EKF Diagnostics

EKF Diagnostics welcomes the recent release of a public health guidance document1 to prevent the development of type 2 diabetes in high risk individuals.

From EKF Diagnostics 15 Aug 2012

Three alternative diabetes markers found

Experts have identified three alternative biomarkers that may be useful for picking up on diabetes risk.

13 Aug 2012

TWi Pharmaceuticals completes AC-201 phase II study on type II diabetes

TWi Pharmaceuticals, Inc., a specialty pharmaceutical company based in Taiwan, today announced its fully owned subsidiary, TWi Biotechnology, Inc. has completed a multinational phase II dose-ranging study of AC-201, an orally available IL-1 Beta modulator, in 259 patients with type II diabetes uncontrolled on up to three oral medications.

6 Aug 2012

Exercise benefits influenced by sRAGE levels in diabetes

Increased levels of the soluble form of the receptor for advanced glycation end products may underly the beneficial effects of exercise in patients with Type 2 diabetes, research shows.

3 Aug 2012

Long-term linagliptin effective treatment for Type 2 diabetes

Linagliptin is an effective and well-tolerated therapy for the long-term management of Type 2 diabetes, say the authors of an open-label extension study published in the International Journal of Clinical Practice.

27 Jul 2012

Diabetes cutoffs don’t quite cut it for South Asians

Individuals of South Asian origin may require closer monitoring for Type 2 diabetes, suggest researchers.

27 Jul 2012

South Asians have higher levels of blood sugar than Europeans: New diabetes study

A new diabetes study at the University of Leicester has discovered that South Asians (people of Indian, Pakistani, Bangladeshi and Sri Lanka origin) have higher levels of blood sugar than white Europeans independent of risk factors that influence sugar levels.

24 Jul 2012

Linagliptin safe and effective for long-term management of type 2 diabetes

An extended trial of a drug for people with type 2 diabetes has confirmed that the oral DPP-4 inhibitor linagliptin is a safe and effective means of lowering glucose levels for up to 102 weeks, either on its own or in combination with other selected oral anti-diabetic medication.

23 Jul 2012